VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research note published on Wednesday morning. The brokerage issued a sell rating on the stock.

Several other research firms also recently weighed in on VNRX. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. D. Boral Capital reiterated a “buy” rating and set a $5.00 price objective on shares of VolitionRx in a report on Wednesday, January 8th.

VolitionRx Stock Performance

VNRX stock opened at $0.63 on Wednesday. The company has a 50 day moving average price of $0.65 and a two-hundred day moving average price of $0.66. The stock has a market capitalization of $58.21 million, a P/E ratio of -1.74 and a beta of 1.20. VolitionRx has a one year low of $0.43 and a one year high of $1.23.

Insiders Place Their Bets

In related news, Director Guy Archibald Innes acquired 174,764 shares of the business’s stock in a transaction on Monday, December 9th. The shares were bought at an average cost of $0.57 per share, with a total value of $99,615.48. Following the completion of the transaction, the director now directly owns 617,085 shares of the company’s stock, valued at $351,738.45. This trade represents a 39.51 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Cameron John Reynolds purchased 139,811 shares of VolitionRx stock in a transaction that occurred on Monday, December 9th. The shares were bought at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the completion of the transaction, the chief executive officer now directly owns 2,117,404 shares in the company, valued at $1,206,920.28. This represents a 7.07 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 358,266 shares of company stock worth $204,212 over the last three months. 12.80% of the stock is owned by insiders.

Institutional Investors Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC boosted its stake in VolitionRx Limited (NYSE:VNRX) by 78.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent reporting period. 8.09% of the stock is owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.